The estimated Net Worth of Jose Breton is at least $40.3 Tysiąc dollars as of 16 March 2021. Mr. Breton owns over 15,000 units of Brickell Biotech Inc stock worth over $40,347 and over the last 5 years he sold BBI stock worth over $0. In addition, he makes $0 as Chief Accounting Officer i Controller at Brickell Biotech Inc.
Jose has made over 1 trades of the Brickell Biotech Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of BBI stock worth $35,250 on 16 March 2021.
The largest trade he's ever made was exercising 15,000 units of Brickell Biotech Inc stock on 16 March 2021 worth over $35,250. On average, Jose trades about 3,000 units every 0 days since 2020. As of 16 March 2021 he still owns at least 17,169 units of Brickell Biotech Inc stock.
You can see the complete history of Mr. Breton stock trades at the bottom of the page.
Jose Breton is Chief Accounting Officer, Controller of the Company. Mr. Breton has served as Brickell’s Controller and Chief Accounting Officer since 2013. Previously, Mr. Breton was an auditor from 2014 to 2015 at Deloitte LLP. Mr. Breton began his career in 2012 as a Client Manager at Global Resource Partners, Inc., an accounting and business advisory firm. In this role, Mr. Breton had overall responsibility for clients’ financial reporting, planning and budgeting, systems of internal controls, corporate and benefits accounting and administration of stock option activity. Mr. Breton holds a B.B.A. degree in Accounting and Finance and a Master’s Degree in Taxation from the University of Miami.
Jose Breton is 30, he's been the Chief Accounting Officer i Controller of Brickell Biotech Inc since 2019. There are 17 older and no younger executives at Brickell Biotech Inc. The oldest executive at Brickell Biotech Inc is Albert Nicholas Marchio II, 69, who is the Chief Financial Officer.
Jose's mailing address filed with the SEC is C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102, BOULDER, CO, 80301.
Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi oraz Gary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
Brickell Biotech Inc executives and other stock owners filed with the SEC include: